Collegium Pharmaceutical (COLL) EBIT Margin (2016 - 2026)

Collegium Pharmaceutical's EBIT Margin history runs 11 years deep, the most recent figure standing at 15.97% for Q1 2026.

• In Q1 2026, EBIT Margin rose 376.0% year-over-year to 15.97%; the TTM figure through Mar 2026 stood at 23.71% (down 399.0% YoY), while the FY2025 annual figure was 23.01%, down 389.0% from the prior year.
• EBIT Margin was 15.97% for Q1 2026 at Collegium Pharmaceutical, down from 29.57% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 437.62% in Q3 2024 to a low of 275.52% in Q1 2022.
• Historically, EBIT Margin has averaged 29.85% across 5 years, with a median of 20.95% in 2024.
• The sharpest annual moves came in 2024 and 2025: EBIT Margin soared 40469 bps in 2024, then sank 40797 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 9.07% in 2022, then soared by 354 bps to 41.2% in 2023, then plunged by 49 bps to 20.95% in 2024, then soared by 41 bps to 29.57% in 2025, then slumped by 46 bps to 15.97% in 2026.
• The last three EBIT Margin figures came in at 15.97% (Q1 2026), 29.57% (Q4 2025), and 29.66% (Q3 2025), per Business Quant data.